Regeneron Pharmaceuticals (REGN) Exchange Rate Effect (2023 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Exchange Rate Effect of -$300000.0 for Q2 2026, down 175.0% year-over-year from $400000.0 in Q2 2025, and up 66.67% quarter-over-quarter from -$900000.0 in Q1 2026.
Powered by 
Analysis
Regeneron Pharmaceuticals (REGN) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Exchange Rate Effect history runs 4 years deep, the most recent figure standing at -$300000.0 for Q2 2026.
- In Q2 2026, Exchange Rate Effect fell 175.0% year-over-year to -$300000.0; the TTM figure through Jun 2026 stood at -$1.9 million (down 272.73% YoY), while the FY2025 annual figure was $300000.0, up 142.86% from the prior year.
- Exchange Rate Effect for Q2 2026 stood at -$300000.0, up from -$900000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $800000.0 in Q3 2024, with the low at -$900000.0 in Q1 2026.
- The 4-year median for Exchange Rate Effect is -$300000.0 (2024), against an average of -$153846.2.
- Peak annual rise in Exchange Rate Effect reached 500.0% in 2024, while the deepest fall reached 450.0% in 2024.
- Regeneron Pharmaceuticals' Exchange Rate Effect stood at $200000.0 in 2023, then slumped by 450.0% to -$700000.0 in 2024, then jumped by 57.14% to -$300000.0 in 2025, then changed by 0.0% to -$300000.0 in 2026.
- Business Quant data shows REGN's Exchange Rate Effect at -$300000.0 in Q2 2026, -$900000.0 in Q1 2026, and -$300000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -287,000.00 |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | -84,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -300,000.00 |
| Mar 31, 2026 | -900,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | -700,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | -300,000.00 |
| Mar 31, 2024 | -500,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | -200,000.00 |
| Jun 30, 2023 | -400,000.00 |